Primary Adrenal Leiomyosarcoma in an Aged Japanese Woman: A Rare Case Report

Chie Aoki¹, Seiichi Tanaka, Kunihiro Suzuki, Masaaki Sagara, and Yoshimasa Aso

Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan

Corresponding author: Chie Aoki, Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan, Tel: +81282872150; Fax: +81282864632; E-mail: c-aoki@dokkyomed.ac.jp

Rec date: Feb 13 2017; Acc date: Mar 16, 2017; Pub date: Mar 22, 2017

Abstract

Primary adrenal leiomyosarcoma is an extremely rare tumor. Here, we report the case of a primary adrenal leiomyosarcoma in an 81-year-old woman. Computed tomography showed a right adrenal tumor (7 cm). There were no abnormal findings on physical examination and her serum adrenal hormone levels were normal. However, 67Gallium scintigraphy showed gallium accumulation at the site of a right adrenal tumor, and malignancy was suspected. The right adrenal tumor was surgically removed and histological examination revealed that it was a leiomyosarcoma. After surgical treatment, the patient was administered different types of chemotherapy but she died of local recurrence 1 year later.

Keywords: Adrenal tumor; Adrenal Leiomyosarcoma; Malignancy

Introduction

Leiomyosarcoma is a rare malignant tumor that occurs in the retroperitoneum, uterus, and the gastrointestinal tract. Primary adrenal leiomyosarcoma is an extremely rare disease and approximately only 30 cases, including our case, have been reported in and outside Japan since it was first described in 1981 [1,2]. Here, we report a case with the final diagnosis of primary adrenal leiomyosarcoma.

Case Report

The subject patient was an 81-year-old woman. She visited a local clinic because of abdominal discomfort in February 2012. Since an abdominal ultrasound showed a mass lesion adjacent to the liver, the patient was referred to our hospital (Dokkyo medical University, Tochigi, Japan) for examination. An abdominal computed tomography scan revealed an adrenal tumor (approximately 7 cm). Therefore, the patient was referred to our department and hospitalized for examination.

The patient's vital signs on admission were height: 144.8 cm, weight: 42.15 kg, body temperature: 36.5°C, blood pressure: 135/66 mmHg, heart rate 72/min, and a normal sinus rhythm. No clear abnormal physical findings or signs of Cushing's syndrome were observed.

A blood test demonstrated a sodium level of 126 mEq/L, which indicated hyponatremia. Electrolyte imbalance or abnormal blood counts were not observed. Although adrenocorticotropic hormone levels were high (162.0 pg/mL), cortisol levels (19.5 µg/mL) were within the normal range and excessive production of corticosteroids/adrenal medullary hormones was not observed. In regards to tumor markers, the levels of neuron-specific enolase and interleukin 2 receptor and thymidine kinase activity were elevated (Table 1).

<table>
<thead>
<tr>
<th>Blood cell count</th>
<th>Tumor marker</th>
<th>Adrenal gland hormone</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC 6300/µL</td>
<td>CEA 1.0 ng/mL</td>
<td>Time</td>
</tr>
<tr>
<td>RBC 401 × 10⁶/µL</td>
<td>NSE47.0 ng/mL</td>
<td>06:00 CS 19.5 µg/mL ACTH 162.0 pg/mL</td>
</tr>
<tr>
<td>Hb 11.7 g/dL</td>
<td>CA19-93 IU/mL</td>
<td>22:00 CS 5.7 µg/mL ACTH 7.8 pg/mL</td>
</tr>
<tr>
<td>Ht 34.6%</td>
<td>IL-2 receptor720 U/mL</td>
<td>Urinary free cortisol 16.5 µg/day</td>
</tr>
<tr>
<td>Pt 31.8 × 10⁹/µL</td>
<td>Thymidine kinase activity 11 U/L</td>
<td>DHEA-S 70 µg/dL (Catecholamine)</td>
</tr>
<tr>
<td>Blood chemistry</td>
<td>Pituitary hormone</td>
<td>Adrenaline: 0.03 ng/mL</td>
</tr>
<tr>
<td>AST 19 IU/L</td>
<td>GH 0.1 ng/mL</td>
<td>Noradrenaline: 0.50 ng/mL</td>
</tr>
<tr>
<td>ALT 9 IU/L</td>
<td>LH 30.80 mIU/mL</td>
<td>Dopamine: 0.02 ng/mL</td>
</tr>
<tr>
<td>ALP 167 IU/L</td>
<td>FSH 80.00 mIU/mL</td>
<td>(24 hour Urinary Catecholamine)</td>
</tr>
</tbody>
</table>
An abdominal contrast-enhanced computed tomography scan revealed a mass lesion ≤ 7 cm in the right adrenal gland that was non-uniformly enhanced, findings suggestive of an adrenal carcinoma (Figure 1a).

67 Gallium scintigraphy demonstrated abnormal accumulation of gallium in the site coincident with the tumor in the right adrenal gland, which is consistent with findings caused by malignancy. Thus, we believed it might be a malignant tumor in the right adrenal gland (Figure 1b). Because surgical treatment was indicated for this case, the patient underwent a translumbar right adrenalectomy in our Department of Urology.

Postoperative pathological examination revealed the following findings: unrestrained invasive hyperplasia of the tumor cells in a diffuse and solid form, atypical spindle cells with oval-shaped nuclei growing in a flowing sequence (Figure 2a). Positive immunostaining results for specific smooth muscle actin and vimentin (Figure 2b). Therefore, the tumor was believed to be a smooth muscle-derived tumor and the patient was diagnosed with adrenal leiomyosarcoma. Postoperative chemotherapy was initiated using mitotane at 500 mg/day. However, mitotane was discontinued after 1 month because adrenal carcinoma was ruled out based on pathological test results. Although ambulatory chemotherapy had been continued using a tegafur-uracil compound agent 200 mg/day since 1 month after surgery, a computed tomography scan 2 months after surgery revealed a local recurrence. Therefore, the patient was readmitted to the Department of Urology. The treatment was changed to Sunitinib at 25 mg/day three months after surgery.

Table 1: Laboratory data on admission.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDH 191 IU/L</td>
<td></td>
<td>Adrenaline: 6.9 μg/day</td>
</tr>
<tr>
<td>PRL 13.30 ng/mL</td>
<td></td>
<td>Noradrenaline: 106 μg/day</td>
</tr>
<tr>
<td>T-Bil 0.4 mg/dL</td>
<td></td>
<td>Dopamine: 430 μg/day</td>
</tr>
<tr>
<td>TSH 3.40 μIU/mL</td>
<td></td>
<td>Thyroid hormone (24 hour Urinaly Metanephrine)</td>
</tr>
<tr>
<td>Cre 0.82 mg/dL</td>
<td></td>
<td>Metanephrine: 0.09 mg/day</td>
</tr>
<tr>
<td>Na 126 mEq/L</td>
<td></td>
<td>Normetanephrine: 0.24 mg/day</td>
</tr>
<tr>
<td>K 4.6 mEq/L</td>
<td></td>
<td>Total metanephrine: 0.33 mg/day</td>
</tr>
<tr>
<td>Cl 88 mEq/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu 98 mg/dL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1a: Abdominal enhanced computed tomography showing a right adrenal tumor.

Figure 1b: 67Gallium scintigraphy showing abnormal accumulation of gallium in the site coincident with the tumor in the right adrenal gland. The region surrounded by a square shows the same area as on the abdominal CT in Figure 1a.

Figure 2a: Hematoxylin & Eosin staining showing the unrestrained invasive hyperplasia of the tumor cells in a diffuse and solid form.
Primary adrenal leiomyosarcoma is believed to develop from the smooth muscle layer of the central vein and its branch veins. Some studies have reported an association with HIV infection and the Epstein-Barr virus infection, and the possibility of a viral infection etiology has been suggested [3-5].

Primary adrenal leiomyosarcoma is characteristic in that in spite of the fast growth of the tumor itself, due to its presence in the retroperitoneal space, subjective symptoms do not usually occur. Because the tumor does not produce hormones, it is not detected until it grows to a huge size. Therefore, primary adrenal leiomyosarcoma is frequently identified due to symptoms such as abdominal pressure and pain caused by the enlarged tumor [6-8].

Since no specific tumor markers for leiomyosarcoma or characteristic imaging findings that allow diagnosis are available, a definite diagnosis is difficult preoperatively. Thus, definitive diagnosis does not occur until after histopathological examination.

In all reported cases, the final diagnosis was reached only after surgery or autopsy. However, one of these cases exhibited elevated neuron-specific enolase levels. The authors of the report suggested that since the plasma neuron-specific enolase levels decreased to the normal range after surgery, an association exists between neuron-specific enolase and primary adrenal leiomyosarcoma, which may allow neuron-specific enolase levels to be used for early detection or as a diagnostic marker. Although we observed elevated neuron-specific enolase levels in our patient, a case without elevated neuron-specific enolase has also been reported [8]. Therefore, more cases and further studies are necessary.

Surgical resection is the basic approach to treating retroperitoneal soft tissue sarcomas. However, a study reported that even when combined resection of surrounding organs was performed, approximately 50% of soft tissue sarcoma cases showed local recurrence and 20% to 30% cases were found to have distant metastasis [9]. The mainstay of treatment is early diagnosis. The survival rate depends on the tumor size and its site of development. Most cases are progressive and the prognosis is extremely poor. Therefore, surgical treatment alone is not sufficient and simultaneous adjuvant therapy is frequently performed [10].

Chemotherapy and radiation therapy are effective adjuvant therapies that destroy and decrease the growth of tumor cells [11]. Some studies have reported that radiation therapy is particularly important in cases where a large tumor locally redevelops or a tumor is located at a site that makes its complete removal difficult [12-14].

Doxorubicin and ifosfamide have been the most effective chemotherapy for soft tissue sarcomas in monotherapy and combination therapy for the past 4-5 years. In addition, taxanes and, in particular, for leiomyosarcoma, gemcitabine plus taxane combination therapy and a new drug, trabectedin, are effective [15]. The molecular targeted drugs Sunitinib, Cediranib, and Sorafenib, and the mammalian target of rapamycin inhibitors appear to be effective for some soft tissue sarcomas. Pazopanib, in particular, is effective for leiomyosarcoma [15].

Due to the preoperative suspicion of adrenal gland cancer, mitotane was administered immediately after the operation until the pathological diagnosis was established. However, the patient underwent postoperative chemotherapy. Once adrenal leiomyosarcoma was confirmed as the pathological diagnosis, we administered Sunitinib, everolimus, and Axitinib for treatment.

Discussion

As stated above, primary adrenal leiomyosarcoma is an extremely rare disease among leiomyosarcomas, with only approximately 30 cases reported in and outside Japan. Most patients with primary adrenal leiomyosarcoma are older and develop a large tumor.
Although the drugs used in this case were different from those used in chemotherapy regimens described earlier, both Sunitinib and everolimus have been reported to be effective for subtypes of soft tissue sarcoma. In particular, Sunitinib has been used in a phase II study to target the soft tissue sarcoma subtypes leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma, and it is expected to be effective for the treatment of leiomyosarcoma [15,16]. We ultimately used Axitinib in the current case because of the adverse effects caused by other drugs, rendering them unusable. The patient received an explanation that Sunitinib, everolimus, and Axitinib are not covered under health insurance for the treatment of leiomyosarcoma, and the drugs were administered with the patient’s consent.

As mentioned above, there is no established method for the treatment of adrenal leiomyosarcoma; therefore, for postoperative chemotherapy, the patient was administered a number of molecular targeted drugs that were not covered by Japanese health insurance but that may have some effect on soft-tissue tumors. However, localized recurrence developed and the patient survived for only 1 year postoperatively. Radiotherapy was not used in this case, but its use in cases of localized recurrence has been reported to be effective. It is possible that its use in addition to chemotherapy should also have been considered in the treatment of our patient [12-14].

Thus, in leiomyosarcoma, a poor prognosis is common even when surgical treatment and chemotherapy/radiation therapy are administered. On the other hand, survival for over 2 years has been reported when a tumor recurrence after a radical operation was treated with radiation/chemotherapy [17]. Another recent study showed that the survival rates in all patients were effective. Thus, an improvement in prognosis can be expected with advances in drug development.

References